Skip to content

Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan

Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06491940
Enrollment
234
Registered
2024-07-09
Start date
2024-08-01
Completion date
2025-07-31
Last updated
2024-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proteinuria

Brief summary

Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage. However, the addition of a diuretic like hydrochlorothiazide may offer synergistic benefits in reducing proteinuria by addressing both the underlying renal pathology and potential volume overload in these patients. The current study aims at determining and comparing the role of losartan alone vs hydrochlorothiazide plus losartan in reducing proteinuria in diabetic nephropathy patients.

Interventions

DRUGLosartan

Patients will receives Losartan (LS) 50 mg per day.

Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.

Sponsors

RESnTEC, Institute of Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients of both genders with ≥18 years of age. * Presence of proteinuria/albuminuria at time of screening. * Creatinine clearance of 30 mL/min or higher.

Exclusion criteria

* A systolic blood pressure of 180 mm Hg or higher, a diastolic blood pressure of 110 mm Hg or higher. * Presence of a second primary renal disease in addition to diabetic nephropathy. * Patients with type 1 diabetes. * A history of a cardiovascular or cerebrovascular event within 3 months before inclusion. * Serum potassium of 6.0 mmol/L or higher. * Transplantation or immunosuppressive treatment. * Contraindication for the use of losartan or hydrochlorothiazide. * Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frameDescription
Reduction of proteinuria4 monthsEfficacy will be labeled yes if reduction of proteinuria/albuminuria from the value before commencing treatment will be observed.

Countries

Pakistan

Contacts

Primary ContactMuhammad Wasim Zahid
drwasimzahid@gmail.com03336361025

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026